Abstract:OBJECTIVE:To assess whether an adjunctive therapy of Sodium Tanshinone II A Sulfonate Injection (STS) is effective and safe in improving clinical outcomes in patients with coronary heart disease (CHD).METHODS:A literature search was conducted through PubMed, the Cochrane Library, Knowledge Infrastructure Databases (CNKI), Chinese Biomedical Literature Database (SinoMed), Chinese Science and Technology Periodical Database (VIP) and Wanfang Database up to August 2017. Randomized controlled trials (RCTs) comparing STS with placebo or no additional treatments on the basis of standard conventional medicine therapies were included. The outcomes were all-cause mortality, major acute cardiovascular events (MACEs), cardiac function and inflammatory factors. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses.RESULTS:A total of 22 RCTs involving 1,873 participants were included. All of the trials used STS as adjunctive treatment to standard conventional medicine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of STS with percutaneous coronary intervention (PCI) or thrombolytic therapy (TT) might be more effective on reduction of all cause death rate than TT alone [risk ratio (RR) 0.25, 95% confidence interval (CI) 0.07 to 0.87] or PCI alone (RR 0.42, 95% CI 0.04 to 4.36). The results of 6 trials comparing STS plus TT with TT alone showed that the addition of STS significantly reduced the incidence of cardiac shock (RR 0.35, 95% CI 0.14 to 0.86), heart failure (RR 0.41, 95% CI 0.20 to 0.83) and arrhythmia (RR 0.21, 95% CI 0.12 to 0.46). STS combined with TT also showed a superior effect on cardiac function and inflammatory factor. No severe adverse event was reported related to STS.CONCLUSIONS:As an adjunctive therapy, STS combined with standard conventional medicine seems to be more effective on all-cause mortality or MACEs than conventional medicine treatment alone with less side effects. However, we cannot make a firm conclusion due to low quality of inclusion trials. Well-designed trials with high methodological quality are needed to validate the effect of STS for CHD patients.

Effect of Sodium Tanshinone II A Sulfonate on the Activity of CYP1A2 in Healthy Volunteers

[A Study on the Effect of Tanshinone II A Against Human Breast Cancer in Vivo].

Effects of Matrine and Oxymatrine on Catalytic Activity of Cytochrome P450s in Rats.

Stephanthraniline A And Cyclosporine A Synergize To Inhibit T-Cell Response In Vitro And In Vivo

Effects of Shuxuetong Injection on Activities of Six Isoforms of Cytochrome P450 in Rats

Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

Determination of Sodium Tanshinone IIA Sulfonate in human plasma by LC-MS/MS and its application to a clinical pharmacokinetic study.

Effects of the Coexisting Diterpenoid Tanshinones on the Pharmacokinetics of Cryptotanshinone and Tanshinone IIA in Rat.

Tanshinone derivatives: a patent review (January 2006 - September 2012)

Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of Salvia miltiorrhiza.

Lower Clearance of Sodium Tanshinone IIA Sulfonate in Coronary Heart Disease Patients and the Effect of Total Bilirubin: a Population Pharmacokinetics Analysis.

Tanshinone IIA increases mRNA expression of efflux transporters in cultured human intestinal cell.

Profiling the metabolic difference of seven tanshinones using high-performance liquid chromatography/multi-stage mass spectrometry with data-dependent acquisition.

Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions Via Improving Cholinergic System

Evaluation of the Effects of Notoginseng Total Saponins (NS), Safflower Total Flavonoids (SF), and the Combination of NS and SF (CNS) on the Activities of Cytochrome P450 Enzymes Using a Cocktail Method in Rats.

Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat

Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells

Sodium Tanshinone ⅡA Sulfonate Injection As Adjunctive Therapy for the Treatment of Heart Failure: A Systematic Review and Meta-Analysis.

Interaction between sodium tanshinone IIA sulfonate and the adriamycin semiquinone free radical: A possible mechanism for antagonizing adriamycin-induced cardiotoxity

Effect of tanshinone II A on COX-2 expression in hepatocellular carcinoma cell line SMMC-7721

Tanshinone IIA: A Promising Natural Cardioprotective Agent